You are here:
Innovative financing mechanism accelerates global roll out of vaccine against world’s leading cause of child deaths
Pneumococcal vaccines are complex vaccines that would normally reach low-income countries 10-15 years after their introduction in industrialised countries.
Thanks to the pneumococcal Advance Market Commitment, children in 57 Gavi-eligible countries are being immunised against the main cause of pneumonia today.
The 2016 Pneumococcal AMC Annual Report gives an overview of the activities linked to the implementation of the pilot Advance Market Commitment from 1 January to 31 December 2016.
It was developed by the AMC Secretariat at Gavi, in collaboration with the World Bank and UNICEF’s Supply Division, and was approved by the Independent Assessment Committee on 10 April 2017.
View previous Annual Reports: 2015 | 2014-2015 | 2013-2014 | 2012-2013 | 2011-2012 | 2010-2011 | 2009-2010
If you represent a vaccine manufacturer and are interested in participating in the pneumococcal AMC, this section explains how to make your offer.
Suppliers must sign a registration agreement relating to the AMC terms and conditions.
UNICEF issues Calls for Supply Offers following the publication of the Strategic Demand Forecast.
Close to 1 million Myanmar children to be protected
Bangladesh introduces pneumococcal vaccine
Niger tackles its two biggest child killers
The pneumococcal Advance Market Commitment is an innovative way to make effective and affordable pneumococcal vaccines available for children in developing countries.
Step by step guide to the method behind the AMC mechanism linking donors, the World Bank, WHO, UNICEF and developing country governments.
Gavi-eligible countries should apply for Gavi pneumococcal vaccine support in the usual way. Countries that are in transition or no longer eligible for other forms of Gavi support, should follow separate application guidelines.
Concerned about the misuse of Gavi resources? Report it now.
© Gavi 2017
modal window here